Ulcerative Colitis

We anticipate selling, general and administrative expenses for 2006 to be approximately 38% of total product revenue.

Additionally for 2006, we anticipate a charge of $4.0 to $4.5 million related to the amortization of intangible assets associated with the InKine merger in 2005 and the acquisition of AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R) in prior years.

For 2006, we expect total Company product revenue will be at least $205 million.

We believe we will be able to deliver earnings per share of at least $0.85, on a fully diluted basis, assuming a 5% tax rate, for the year ending December 31, 2006.

During 2006 we intend to continue increasing profits by focusing our efforts and leveraging our resources to grow our established therapeutic franchises.

We believe that our focused and leveraged efforts should generate operating margins in excess of 30% in 2007 and increasing thereafter." Commenting on 2005, Carolyn Logan, President and Chief Executive Officer, stated, "We are pleased with the progress the Company made during the year to build and expand upon our three therapeutic franchises in gastroenterology: inflammatory bowel disease; bacteria-related disease and bowel-cleansing.

COLAZAL continues to provide a solid b...

"So what I tried to do in this article is to point out that the continued presence of these organisms in human society may actually be beneficial to the host and that is why they are tolerated by the immune system." It’s an intriguing idea that requires more research in animal models.

"We don’t know what to look for per se," he said.

"But we can guess that since a persistently infected host is constantly having its immune system stimulated and refined, that may provide it with resistance to other things." He wondered whether, as seen with H.

pylori, humans are also unknowingly causing the disappearance of other things that have been with us for all of our evolution, and that might play some role in our health.

"Could it be this that is responsible for some of the things we see such as the failure of the immune system to act appropriately?

" he asked.

The only answer to date is: "It’s complicated." Instead of a persistent infection, some people get very ill from organisms such as Salmonella, H.

pylori, tuberculosis and meningitis.

How the immune system responds differently in individuals demands further research.

Falkow credits his colleagues for providing the fodder for his essay.

Weitere Informationen:www.stanford.edu Weitere Meldungen im Bereich Medizin Gesundheit 24.02.2006 ...